IMGT Corporation Limited Logo

IMGT Corporation Limited

Develops a drug delivery platform using ultrasound and nanotech for oncology.

456570 | KO

Overview

Corporate Details

ISIN(s):
KR7456570001
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 돌마로 172, 성남시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

IMGT Corporation Limited is a clinical-stage biotechnology company specializing in the development of a proprietary drug delivery platform for intractable diseases. Founded in 2010, the company's core technology integrates focused ultrasound with nanotechnology-based medicines to enhance the targeted delivery of therapeutic agents, including gene therapies and immunotherapy solutions. This innovative approach is designed to overcome biological barriers, enabling drugs to more effectively penetrate cancer cells. IMGT's development pipeline includes ultrasonic medical devices and a focus on oncology, with clinical trials underway for treatments such as pancreatic cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-04 00:00
Report Publication Announcement
기업설명회(IR)개최결과
Korean 6.6 KB
2025-05-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-05-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 145.3 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-13 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.8 KB
2025-05-12 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 102.6 KB
2025-04-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 71.2 KB
2025-04-25 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 113.9 KB
2025-04-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자_우선주)
Korean 5.3 KB
2025-04-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 5.2 KB
2025-04-21 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 108.1 KB
2025-04-14 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 94.0 KB
2025-04-11 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 89.7 KB
2025-04-07 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 393.7 KB
2025-03-31 00:00
Audit Report / Information
감사보고서제출
Korean 10.5 KB

Automate Your Workflow. Get a real-time feed of all IMGT Corporation Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IMGT Corporation Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IMGT Corporation Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Material Group inc. Logo
A professional services firm offering PR consulting, marketing, and brand strategy.
Japan
156A
Medesis Pharma S.A. Logo
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
France
ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.
Poland
MDB
Medpace Holdings, Inc. Logo
Global CRO providing full-service clinical development to biotech, pharma & medical device industries.
United States of America
MEDP
Develops biomarker-based precision therapies for oncology and other incurable diseases.
South Korea
235980
Medrx Co.,Ltd. Logo
Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.
Japan
4586
Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan
7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden
IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D

Talk to a Data Expert

Have a question? We'll get back to you promptly.